Mr. Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. He previously served as Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies. Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company now owned by Orchestra BioMed. Mr. Hochman has over 25 years of healthcare entrepreneurial, venture capital, and investment banking experience. From December 2016 to September 2023, Mr. Hochman served as a member of the board of directors of Motus GI (Nasdaq: MOTS), a Nasdaq-listed medical technology company in which Orchestra has a strategic investment and as its Chairman of the Board from December 2016 to April 2023. Mr. Hochman was a co-founder and until September 2020 served as a board member of Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. Prior to joining Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early-stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc., during which time he led financing transactions for over twenty early-stage companies, raising over $420 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer-lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million. Mr. Hochman earned a B.A. with honors from the University of Michigan.

Vivek Y. Reddy, MD is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai. He is also Executive Chairman of the OBIO's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board Dr. Reddy is one of the nation’s premier cardiac electrophysiologists, leading a team of physician-scientists who are developing and testing advanced therapies for cardiac arrhythmias – including atrial fibrillation and ventricular tachycardias, the most common cause of sudden cardiac death. His team offers the full spectrum of arrhythmia therapies. Dr. Reddy’s pioneering clinical research is changing the way cardiac patients are treated and cured. Under his leadership, Mount Sinai is the lead investigator on several multinational clinical trials exploring new arrhythmia procedures and technologies. In addition, in 2014 Dr. Reddy implanted inside a patient's heart the world’s first miniature leadless pacemaker in the United States at The Mount Sinai Hospital. The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.

Dr. Marat Fudim is an Associate Professor and heart failure cardiologist at the Duke University Medical Center. He completed his medical school in Germany, residency at Vanderbilt and cardiology fellowship at Duke. He currently serves as the Medical Director for the Clinical Research Unit, Heart Failure Remote Monitoring and Heart Failure Device Clinic. He won the 2021 American College of Cardiology Douglas Zipes Distinguished Young Investigator Award. His research interest is in the pathophysiology of HF, and heart failure with preserved ejection fraction specifically.

Dr. Fischer has served as Sr. Vice President (VP), Medical Affairs and Innovation for Orchestra BioMed since January 2023. Dr. Fischer brings with him extensive knowledge as a former practicing electrophysiologist along with vast industry experience in management and clinical research. Dr. Fischer has worked with both startup and large publicly traded companies, providing him with an in-depth understanding of the unique challenges associated with development and commercialization of novel medical technologies. Immediately prior to joining Orchestra BioMed, Dr. Fischer was CEO of ElectroPhysiology Frontiers, S.p.A. in Milan. From 2012 – 2021, he worked for Abbott and St. Jude Medical where he held various leadership roles including VP, Global Education and Medical Director, Divisional VP Medical Affairs and Medical Director, and Chief Medical Officer, Cardiac Rhythm Management. Prior to joining industry, Dr. Fischer was Director, Pacemaker and Defibrillator Therapy, for Mount Sinai Medical Center in NYC from 2006 to 2017. He has lectured at national and international scientific congresses, trained and proctored physicians around the world, and authored numerous original publications, invited reviews, and book chapters. Dr. Fischer holds a Bachelor of Arts degree from the University of Maryland and a Doctor of Medicine degree from Tel Aviv University.

Mr. Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. He previously served as Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies. Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company now owned by Orchestra BioMed. Mr. Hochman has over 25 years of healthcare entrepreneurial, venture capital, and investment banking experience. From December 2016 to September 2023, Mr. Hochman served as a member of the board of directors of Motus GI (Nasdaq: MOTS), a Nasdaq-listed medical technology company in which Orchestra has a strategic investment and as its Chairman of the Board from December 2016 to April 2023. Mr. Hochman was a co-founder and until September 2020 served as a board member of Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. Prior to joining Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early-stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc., during which time he led financing transactions for over twenty early-stage companies, raising over $420 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer-lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million. Mr. Hochman earned a B.A. with honors from the University of Michigan.

Dr. Marat Fudim is an Associate Professor and heart failure cardiologist at the Duke University Medical Center. He completed his medical school in Germany, residency at Vanderbilt and cardiology fellowship at Duke. He currently serves as the Medical Director for the Clinical Research Unit, Heart Failure Remote Monitoring and Heart Failure Device Clinic. He won the 2021 American College of Cardiology Douglas Zipes Distinguished Young Investigator Award. His research interest is in the pathophysiology of HF, and heart failure with preserved ejection fraction specifically.

Vivek Y. Reddy, MD is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai. He is also Executive Chairman of the OBIO's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board Dr. Reddy is one of the nation’s premier cardiac electrophysiologists, leading a team of physician-scientists who are developing and testing advanced therapies for cardiac arrhythmias – including atrial fibrillation and ventricular tachycardias, the most common cause of sudden cardiac death. His team offers the full spectrum of arrhythmia therapies. Dr. Reddy’s pioneering clinical research is changing the way cardiac patients are treated and cured. Under his leadership, Mount Sinai is the lead investigator on several multinational clinical trials exploring new arrhythmia procedures and technologies. In addition, in 2014 Dr. Reddy implanted inside a patient's heart the world’s first miniature leadless pacemaker in the United States at The Mount Sinai Hospital. The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.

Mr. Sherman has served as President, Chief Operating Officer and a member of the Board of Orchestra BioMed since May 2018. From 2009 until December 2019, Mr. Sherman served as Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies. He co-founded Orchestra BioMed and its wholly owned subsidiaries Caliber, BackBeat and Freehold. Mr. Sherman also served as Chief Technical Officer of Accelerated Technologies, Inc. (ATI), a medical device accelerator company now owned by Orchestra BioMed. Mr. Sherman has over 25 years of management and entrepreneurial experience in the medical technology industry spanning interventional cardiology, cardiac electrophysiology, sudden cardiac death, stroke, surgery, GI, and neurovascular therapies. Mr. Sherman served as Chief Executive Officer and a Director of Caliber since 2009. He was a co-founder and served on the Board of BackBeat since 2010. He was a co-founder and served as Chief Executive Officer and a director of FreeHold since 2011. From 2009 until 2016, he served on the board of directors of Vivasure. He served as a director of Motus GI (Nasdaq: MOTS), a Nasdaq-listed medical technology company that Orchestra also has a strategic holding in, from December 2016 to September 2023. From February 2002 until March 2008, Mr. Sherman held various positions in executive management for Cordis Neurovascular (CNV), a Johnson & Johnson company, including Executive Director R&D and Director of Strategic Marketing for stroke products. He had worldwide responsibility for all neurovascular R&D and global strategic marketing responsibilities for the stroke franchise, including budgets, portfolio of products and strategic planning. Mr. Sherman made significant contributions to the design and commercialization of a series of key products including the Enterprise Vascular Reconstruction Device and the Orbit Embolic Coil. From January 1997 until February 2002, Mr. Sherman played an integral role in the formation and development of Revivant Corp (acquired by Zoll) while working with Thomas J. Fogarty, M.D. at Fogarty Engineering. He was Revivant’s first employee and managed the design, development, and testing of the AutoPulse device from concept through market introduction. In addition to the R&D related activities, Mr. Sherman supported the clinical research, marketing, and intellectual property efforts. The AutoPulse is a lightweight, portable tool replacing the need for manual chest compressions during cardio-pulmonary resuscitation (CPR) for patients suffering from sudden cardiac arrest. From January 1995 until January 1997, Mr. Sherman held positions in research and development for Cardiac Pathways Corp., prior to its acquisition by Boston Scientific. Prior to Cardiac Pathways, he worked at Baxter Healthcare. In each of these companies, he participated in the creation, development and launch of products. Mr. Sherman has authored more than 85 U.S. patents with an additional 90+ published applications. He earned a BS degree in Bioengineering from the University of California, San Diego.

Allen Jeremias, MD, MSc, is the Director of the Cardiac Catheterization Laboratory at St. Francis Hospital & Heart Center, New York and an Executive Director for Optimizing PCI (OPCI). He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high-volume interventional cardiologist since 2006, specializing in complex coronary intervention and CTO procedures. He has been recognized as a top doctor by Castle Connolly and has received CMS Meaningful Use Stage Certifications from the Cerner Corporation. Dr. Jeremias is considered one of the foremost authorities in coronary physiology and intravascular imaging to optimize coronary interventions and is leading several major clinical trials as the global principal investigator, including DEFINE PCI, All Rise, Virtue ISR and the DEFINE GPS study which is a landmark randomized clinical trial in the use of coronary physiology for PCI guidance.

Dean J. Kereiakes, M.D., PhD (Hon), FACC, MSCAI is Chairman of The Christ Hospital Heart and Vascular Institute, Medical Director of The Christ Hospital Research Institute, Professor of Medicine, University of Cincinnati, Clinical Professor of Medicine, The Ohio State University and and Professor of Medicine, Northeast Ohio College of Medicine. Dr. Kereiakes received his M.D. degree and was valedictorian of his graduating class at the University of Cincinnati in Ohio. Postgraduate training included residency at the University of California, San Francisco (UCSF) and senior residency at the Massachusetts General Hospital, Boston. Chief Resident, Internal Medicine as well as cardiology fellowship at UCSF and coronary angioplasty training at both the San Francisco Heart Institute and the Sequoia Hospital. Dr. Kereiakes has published over 1,300 peer-reviewed medical journal articles, abstracts and book chapters. He has served on the Editorial Boards of every major cardiovascular journal in the U.S., was previously Section Editor, Circulation and is currently Deputy Editor, the Journal for the Society of Cardiovascular Angiography and Interventions. He has served as National/International Principal Investigator on 28 pivotal trials for U.S. FDA approval of novel cardiovascular devices and has performed more than 30,000 catheterization laboratory procedures. He was founder and original Medical Director of The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital, one of the top clinical research sites in the United States. He was Founder and CEO of The Ohio Heart Health Center, at one time the largest cardiology subspecialty group in Ohio, which subsequently become the cardiovascular service line for The Christ Hospital. Dr. Kereiakes has been recognized with “Master” (MSCAI) distinction by The Society for Cardiovascular Angiography and Interventions (SCAI). He was honored with “Outstanding Alumnus” (2008), Honorary Doctorate of Sciences (2014), and the William Howard Taft Medal for Achievement (2024) by the University of Cincinnati. He received the American Heart Association Samuel Kaplan Visionary Award (2000) and the Cincinnati Business Courier Innovator Award (1998 and 2025). He has received both the Scottsdale Interventional Forum (SIF) Lifetime Achievement Award (2024) and the Helping Hearts Lifetime Service Award (2025) from SCAI.

Mr. Sherman has served as President, Chief Operating Officer and a member of the Board of Orchestra BioMed since May 2018. From 2009 until December 2019, Mr. Sherman served as Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies. He co-founded Orchestra BioMed and its wholly owned subsidiaries Caliber, BackBeat and Freehold. Mr. Sherman also served as Chief Technical Officer of Accelerated Technologies, Inc. (ATI), a medical device accelerator company now owned by Orchestra BioMed. Mr. Sherman has over 25 years of management and entrepreneurial experience in the medical technology industry spanning interventional cardiology, cardiac electrophysiology, sudden cardiac death, stroke, surgery, GI, and neurovascular therapies. Mr. Sherman served as Chief Executive Officer and a Director of Caliber since 2009. He was a co-founder and served on the Board of BackBeat since 2010. He was a co-founder and served as Chief Executive Officer and a director of FreeHold since 2011. From 2009 until 2016, he served on the board of directors of Vivasure. He served as a director of Motus GI (Nasdaq: MOTS), a Nasdaq-listed medical technology company that Orchestra also has a strategic holding in, from December 2016 to September 2023. From February 2002 until March 2008, Mr. Sherman held various positions in executive management for Cordis Neurovascular (CNV), a Johnson & Johnson company, including Executive Director R&D and Director of Strategic Marketing for stroke products. He had worldwide responsibility for all neurovascular R&D and global strategic marketing responsibilities for the stroke franchise, including budgets, portfolio of products and strategic planning. Mr. Sherman made significant contributions to the design and commercialization of a series of key products including the Enterprise Vascular Reconstruction Device and the Orbit Embolic Coil. From January 1997 until February 2002, Mr. Sherman played an integral role in the formation and development of Revivant Corp (acquired by Zoll) while working with Thomas J. Fogarty, M.D. at Fogarty Engineering. He was Revivant’s first employee and managed the design, development, and testing of the AutoPulse device from concept through market introduction. In addition to the R&D related activities, Mr. Sherman supported the clinical research, marketing, and intellectual property efforts. The AutoPulse is a lightweight, portable tool replacing the need for manual chest compressions during cardio-pulmonary resuscitation (CPR) for patients suffering from sudden cardiac arrest. From January 1995 until January 1997, Mr. Sherman held positions in research and development for Cardiac Pathways Corp., prior to its acquisition by Boston Scientific. Prior to Cardiac Pathways, he worked at Baxter Healthcare. In each of these companies, he participated in the creation, development and launch of products. Mr. Sherman has authored more than 85 U.S. patents with an additional 90+ published applications. He earned a BS degree in Bioengineering from the University of California, San Diego.

Allen Jeremias, MD, MSc, is the Director of the Cardiac Catheterization Laboratory at St. Francis Hospital & Heart Center, New York and an Executive Director for Optimizing PCI (OPCI). He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high-volume interventional cardiologist since 2006, specializing in complex coronary intervention and CTO procedures. He has been recognized as a top doctor by Castle Connolly and has received CMS Meaningful Use Stage Certifications from the Cerner Corporation. Dr. Jeremias is considered one of the foremost authorities in coronary physiology and intravascular imaging to optimize coronary interventions and is leading several major clinical trials as the global principal investigator, including DEFINE PCI, All Rise, Virtue ISR and the DEFINE GPS study which is a landmark randomized clinical trial in the use of coronary physiology for PCI guidance.

Dean J. Kereiakes, M.D., PhD (Hon), FACC, MSCAI is Chairman of The Christ Hospital Heart and Vascular Institute, Medical Director of The Christ Hospital Research Institute, Professor of Medicine, University of Cincinnati, Clinical Professor of Medicine, The Ohio State University and and Professor of Medicine, Northeast Ohio College of Medicine. Dr. Kereiakes received his M.D. degree and was valedictorian of his graduating class at the University of Cincinnati in Ohio. Postgraduate training included residency at the University of California, San Francisco (UCSF) and senior residency at the Massachusetts General Hospital, Boston. Chief Resident, Internal Medicine as well as cardiology fellowship at UCSF and coronary angioplasty training at both the San Francisco Heart Institute and the Sequoia Hospital. Dr. Kereiakes has published over 1,300 peer-reviewed medical journal articles, abstracts and book chapters. He has served on the Editorial Boards of every major cardiovascular journal in the U.S., was previously Section Editor, Circulation and is currently Deputy Editor, the Journal for the Society of Cardiovascular Angiography and Interventions. He has served as National/International Principal Investigator on 28 pivotal trials for U.S. FDA approval of novel cardiovascular devices and has performed more than 30,000 catheterization laboratory procedures. He was founder and original Medical Director of The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital, one of the top clinical research sites in the United States. He was Founder and CEO of The Ohio Heart Health Center, at one time the largest cardiology subspecialty group in Ohio, which subsequently become the cardiovascular service line for The Christ Hospital. Dr. Kereiakes has been recognized with “Master” (MSCAI) distinction by The Society for Cardiovascular Angiography and Interventions (SCAI). He was honored with “Outstanding Alumnus” (2008), Honorary Doctorate of Sciences (2014), and the William Howard Taft Medal for Achievement (2024) by the University of Cincinnati. He received the American Heart Association Samuel Kaplan Visionary Award (2000) and the Cincinnati Business Courier Innovator Award (1998 and 2025). He has received both the Scottsdale Interventional Forum (SIF) Lifetime Achievement Award (2024) and the Helping Hearts Lifetime Service Award (2025) from SCAI.

Mr. Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. He previously served as Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies. Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company now owned by Orchestra BioMed. Mr. Hochman has over 25 years of healthcare entrepreneurial, venture capital, and investment banking experience. From December 2016 to September 2023, Mr. Hochman served as a member of the board of directors of Motus GI (Nasdaq: MOTS), a Nasdaq-listed medical technology company in which Orchestra has a strategic investment and as its Chairman of the Board from December 2016 to April 2023. Mr. Hochman was a co-founder and until September 2020 served as a board member of Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. Prior to joining Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early-stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc., during which time he led financing transactions for over twenty early-stage companies, raising over $420 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer-lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million. Mr. Hochman earned a B.A. with honors from the University of Michigan.